Two Sigma Advisers
NAGE

Two Sigma Advisers’s Niagen Bioscience NAGE Stock Holding History

Two Sigma Advisers’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,800
Closed -$87.8K – 2299
2025
Q4 		$87.8K Buy
+13,800
New +$96K ﹤0.01% 2245
2023
Q2 		– Sell
-30,100
Closed -$46.1K – 2709
2023
Q1 		$46.1K Sell
30,100
-19,100
-39% -$34K ﹤0.01% 2458
2022
Q4 		$82.7K Buy
49,200
+7,200
+17% +$11.4K ﹤0.01% 2317
2022
Q3 		$52K Sell
42,000
-10,300
-20% -$16.6K ﹤0.01% 2372
2022
Q2 		$87K Buy
52,300
+200
+0.4% +$391 ﹤0.01% 2405
2022
Q1 		$128K Sell
52,100
-12,900
-20% -$35.2K ﹤0.01% 2467
2021
Q4 		$243K Buy
+65,000
New +$351K ﹤0.01% 2217
2021
Q1 		– Sell
-21,800
Closed -$105K – 2756
2020
Q4 		$105K Sell
21,800
-4,300
-16% -$21K ﹤0.01% 2269
2020
Q3 		$105K Buy
26,100
+5,300
+25% +$25.6K ﹤0.01% 2272
2020
Q2 		$95K Buy
+20,800
New +$93.1K ﹤0.01% 2365

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Advisers's NAGE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 13,800 shares — an estimated $87.8K sold.

Two Sigma Advisers first reported a position in NAGE in Q2 2020 and held it in 10 quarters. The position peaked at $243K in Q4 2021. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 13,800 Niagen Bioscience shares in Q1 2026, an estimated $87.8K.
  • Two Sigma Advisers first reported a position in Niagen Bioscience in Q2 2020 and held it in 10 quarters.
  • Two Sigma Advisers's Niagen Bioscience position peaked at $243K in Q4 2021.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.